eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
6/2024
vol. 41
 
Share:
Send email
Share:
Original paper

Significance of HLA-B*15 in three pemphigus patients with rituximab-triggered severe cutaneous drug reactions

Tang Jun-ting
1
,
Tu Ying
1
,
Sun Dong-Jie
1
,
Nong Xiang
1
,
Cao Can
1
,
Du Si-Cheng
1
,
Cun Yue-Ting
1
,
He Li
1

  1. Department of Dermatology and Venerology, First Affiliated Hospital of Kunming Medical University, Kunming, China
Adv Dermatol Allergol 2024; XLI (6): 566-570
DOI: https://doi.org/10.5114/ada.2024.145439
Online publish date: 2024/12/02
Article file
- Significance (1).pdf  [0.17 MB]
Get citation
 
 
1. Drenovska K, Ivanova M, Vassileva S, et al. Association of specific HLA alleles and haplotypes with pemphigus vulgaris in the Bulgarian population. Front Immunol 2022; 13: 901386.
2. Zhang J, Huang X, Zhang Z,et al. Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single-center prospective cohort study. J Am Aca Dermatol 2023; 88: 500-2.
3. Mokos M, Lakoš Jukić I, Marinović B. Transient worsening of pemphigus vulgaris resembling toxic epidermal necrolysis after the first cycle of rituximab therapy. Dermatol Ther 2022; 35: e15469.
4. Kenneth PA, Amy JF, Timothy DM. Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. Comp Med 2005; 55: 377-81.
5. Bae S, Kim Y, Yoon JY, et al. Toxic epidermal necrolysis after rituximab therapy for immune thrombocytopenic purpura. Korean J Hematol 2009; 44: 108-12.
6. Fallon M, Heck J. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract 2015; 21: 388-92.
7. Didona D, Paolino G, Garcovich S, et al. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur Acad Dermatol Venereol 2016; 30: e83-84.
8. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 1025-32.
9. Park H, Yun J, Kang D, et al. Unique clinical characteristics and prognosis of allopurinol-induced severe cutaneous adverse reactions. J Allergy Clin Immunol Prac 2019; 7: 2739-49.e3.
10. Carr D, Chaponda M, Jorgensen A, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis 2013; 56: 1330-9.
11. Bharadwaj M, Illing P, Kostenko L. Personalized medicine for HLA-associated drug-hypersensitivity reactions. Per Med 2010; 7: 495-516.
12. El-Zawahry B, Bassiouny D, Hegazy R, et al. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs. Arch Dermatol Res 2017; 309: 551-6.
13. Tang JT, Li YY, Zhang Y, et al. HIV infection confers distinct mechanisms in severe drug eruption: endogenous virus activation with aberrant Th2/Th1 and CD8 T cells function.
14. Clin Exp Pharmacol Physiol 2020; 47: 1005-13.
15. Li YY, Jin YM, He LP, et al. Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China. Sci Rep 2016; 6: 35938.
16. Olson E, Geng J, Raghavan M. Polymorphisms of HLA-B: influences on assembly and immunity. Curr Opin Immunol 2020; 64: 137-45.
17. Borchers A, Lee J, Naguwa S, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
18. Miyagawa F, Asada H. Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Int J Mol Sci 2021; 22: 2147.
19. Liu YW, Yu YC, Nie XL, et al. Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis. Pharmacogenomics 2018; 19: 547-52.
20. Manuyakorn W, Likkasittipan P, Wattanapokayakit S, et al. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. Epilepsy Res 2020; 162: 106321.
21. Sukasem C, Pratoomwun J, Satapornpong P, et al. Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes. Clin Pharmacol Ther 2020; 108: 1078-89.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.